Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro.

@article{Yusa2004AcquisitionOM,
  title={Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro.},
  author={Keisuke Yusa and Shinji Harada},
  journal={Current pharmaceutical design},
  year={2004},
  volume={10 32},
  pages={
          4055-64
        }
}
  • Keisuke Yusa, Shinji Harada
  • Published in Current pharmaceutical design 2004
  • Biology, Medicine
  • Protease inhibitors are effective antiviral agents which can lead to a severe decrease in HIV RNA copies in plasma of naive patients, however even successful suppression of the virus with antiretroviral agents including protease inhibitor(s) (PI(s)) generates PI-resistant HIV-1 after long term treatment. Occasionally HIV-1 acquires cross-resistance to other PIs with which the patients have not been treated. Cross-resistance to multiple PIs (multi-PI resistance) leads to a restricted salvage… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Topics from this paper.

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 10 CITATIONS

    Lopinavir/Ritonavir

    VIEW 5 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes

    VIEW 1 EXCERPT
    CITES BACKGROUND